ARTICLE | Clinical News
CK-2017357 regulatory update
March 15, 2010 7:00 AM UTC
FDA granted Orphan Drug designation to Cytokinetics' CK-2017357 to treat amyotrophic lateral sclerosis (ALS). The company plans to start a Phase II trial for the skeletal muscle troponin activator thi...